New patient studies surrounding this compound, specifically the 120 milligram formulation branded as ZPHC, reveal a considerable impact on weight loss and associated chronic factors. Scientists anticipate that this combined agonist , influencing both GLP-1 and GIP systems, may provide a substantial improvement in the treatment of overweight and re